Healthcare -
Biotechnology - NASDAQ - US
$ 1.8608
-3.1 %
$ 28.8 M
Market Cap
-0.74
P/E
1. INTRINSIC VALUE
Balance Sheet
CASI Pharmaceuticals, Inc.
| Current Assets | 39.6 M |
| Cash & Short-Term Investments | 16.1 M |
| Receivables | 15.3 M |
| Other Current Assets | 8.14 M |
| Non-Current Assets | 13.9 M |
| Long-Term Investments | 1.72 M |
| PP&E | 11.4 M |
| Other Non-Current Assets | 825 K |
| Current Liabilities | 36.5 M |
| Accounts Payable | 2.72 M |
| Short-Term Debt | 19.6 M |
| Other Current Liabilities | 14.1 M |
| Non-Current Liabilities | 15.4 M |
| Long-Term Debt | 2.54 M |
| Other Non-Current Liabilities | 12.8 M |
EFFICIENCY
Earnings Waterfall
CASI Pharmaceuticals, Inc.
| Revenue | 28.5 M |
| Cost Of Revenue | 17.4 M |
| Gross Profit | 11.1 M |
| Operating Expenses | 50.8 M |
| Operating Income | -39.6 M |
| Other Expenses | -363 K |
| Net Income | -39.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CASI Pharmaceuticals, Inc.
| Net Income | -39.3 M |
| Depreciation & Amortization | 2.33 M |
| Capital Expenditures | -240 K |
| Stock-Based Compensation | 1.31 M |
| Change in Working Capital | 771 K |
| Others | 7.49 M |
| Free Cash Flow | -29.5 M |
Wall Street Analysts Price Targets
CASI Pharmaceuticals, Inc.
CASI has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CASI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CASI Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CASI Pharmaceuticals Provides Business and Clinical Update
BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m.
accessnewswire.com
- 4 weeks ago
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the quarter ended March 31, 2025. Dr. Wei-Wu He, Ph.D.
accessnewswire.com
- 1 month ago
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has entered into a definitive Equity and Assets Transfer Agreement (the "Equity and Assets Transfer Agreement") with Kaixin Pharmaceuticals Inc. ("Kaixin Pharmaceuticals"), a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company and two direct wholly-owned subsidiaries of the Company in China (the "Target Companies"), pursuant to which the Company shall sell and transfer, and Kaixin Pharmaceuticals shall purchase and acquire, 100% equity interests in both Target Companies (the "Target Equity Interests"), and all licensing rights, distribution rights, supply arrangements and related rights related to BI-1206 (in China), CID-103(in Asia excluding Japan) and Thiotepa (in China excluding Hong Kong, Macau and Taiwan) (the "Target Pipeline Products") for an aggregate purchase price of $20.0 million, which shall include assumption of up to $20.0 million of indebtedness of the Company (the "Transaction"). The closing of the Transaction shall be subject to certain customary conditions, including resolution of certain judicial freeze on the Target Equity Interests issued in connection with certain ongoing legal dispute of the Company.
accessnewswire.com
- 1 month ago
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated May 5, 2025 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum MVLS of $35 million (the "MVLS Requirement"), and Nasdaq Listing Rule 5810(c)(3)(C) specifies that a deficiency occurs if the MVLS falls below this threshold for 30 consecutive business days.
accessnewswire.com
- 1 month ago
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (the "Proposal Letter"), dated April 2, 2025, from Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company, to acquire the entire business operations of the Company in China and all license-in, distribution and related rights in Asia (excluding Japan) related to certain pipeline products of the Company, including BI-1206, CID-103 and Thiotepa, for an aggregate purchase price of $20.0 million, which shall include assumption of approximately $20.0 million of indebtedness of the Company (the "Proposed Transaction"). The Proposal Letter updates the preliminary non-binding proposal letter submitted by Dr. He to the Company on June 21, 2024.
accessnewswire.com
- 2 months ago
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024. Wei-Wu He, Ph.D.
accessnewswire.com
- 2 months ago
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China. "Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinical development.
accesswire.com
- 5 months ago
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases.
accesswire.com
- 7 months ago
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.
accesswire.com
- 7 months ago
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C.
prnewswire.com
- 9 months ago
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a period of significant progress for CASI as we shifted our Company's strategy to the development of therapeutics for organ transplant rejection and autoimmune disease," said Dr. Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals.
prnewswire.com
- 10 months ago
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
investorplace.com
- 10 months ago
8. Profile
Summary
CASI Pharmaceuticals, Inc. CASI
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 28.8 M
Dividend Yield
0.00%
Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Contact
9620 Medical Center Drive, Beijing, MD, 20850
https://www.casipharmaceuticals.com
IPO
Date
June 12, 1996
Employees
233
Officers
Ms. Wei Gao
Senior Vice President & General Counsel
Dr. Daniel Lang M.D.
MD, Senior Vice President & Chief Financial Officer
Ms. Kun Qian
Vice President & Global Controller
Dr. Wei Zhang Ph.D.
Senior Vice President
Ms. Chunhua Wang
Chief Operating Officer
Dr. James E. Goldschmidt Ph.D.
Chief Business Development Officer
Dr. Wei-Wu He Ph.D.
Chairman & Chief Executive Officer
Dr. Alexander A. Zukiwski M.D.
Executive Vice President & Global Chief Medical Officer
Mr. Hai Huang
Global Chief Commercial Officer & GM of CASI China